Breast cancer outcomes improved with CDK4/6 inhibitor treatment

https://www.facingourrisk.org/XRAY/MBC-outcomes-with-CDK-inhibitor-Ibrance-palbociclib

Full article: https://pubmed.ncbi.nlm.nih.gov/35552673/

A study showed that people with metastatic breast cancer who took an oral drug known as a CDK4/6 inhibitor combined with hormone therapy did better than people who took hormone therapy alone. The drug combination improved the length of time before cancer worsened or returned. After six years of treatment, people who took this drug combination lived longer compared to those who took hormone therapy alone. (Posted 4/5/23)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

What treatment therapy or therapies are best for me?
Should I consider treatment with a CDK4/6 inhibitor for my metastatic breast cancer?
What side effects might I have with a CDK4/6 inhibitor?
Should I have biomarker testing of my tumor?
Are there clinical trials enrolling participants with metastatic breast cancer that are appropriate for me?

Open Clinical Trials

You can search for clinical trials for people with HR-positive or ER-positive metastatic breast cancer here.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.